Development and Validation of a Cytokine‐Based Predictive Model for Acute GvHD and Composite Outcomes in ATG–Based Haploidentical Hematopoietic Stem Cell Transplantation
Mediators of Inflammation · 2026-01 · 2026 (1)
DOI: 10.1155/mi/3165406 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediators of Inflammation, online erschienen am 30.06.2026. Verfasst von Yiyin Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The Firs…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Cytokines, Antilymphocyte Serum. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions.
Abstract (Originalsprache)
Background
Acute graft‐versus‐host disease (aGvHD) stands as a critical complication following haploidentical hematopoietic stem cell transplantation (haplo‐HSCT). Most existing predictive models, predominantly derived from HLA‐matched donor cohorts, have been utilized for nonrelapse mortality (NRM) prediction; however, their utility in predicting aGvHD risk specifically in haplo‐HSCT recipients receiving antithymocyte globulin (ATG)–based prophylaxis warrants further validation.
Methods
A total of 280 patients undergoing ATG–based haplo‐HSCT were retrospectively analyzed across two medical centers, split into training, internal test, and external validation cohorts. We first evaluated the predictive accuracy of the previously established Mount Sinai Acute GvHD International Consortium (MAGIC) algorithm for aGvHD, steroid‐refractory aGvHD (SR‐aGvHD). Subsequently, plasma concentrations of candidate cytokines (ST2, REG3α, Elafin, and TNFRI), selected a priori for their links to epithelial injury and inflammatory signaling in GvHD, were assessed for their predictive and causal relationships with aGvHD using logistic regression, weighted average area under the curve (wAUC), Mendelian randomization (MR), and restricted cubic spline (RCS) analyses. A new predictive model (the HAG model) was constructed based on identified key cytokines and validated across multicenter cohorts. MR analyses utilized external genome‐wide association (GWAS) datasets to validate the reliability of identified cytokines. A visual interface for the model was created using R Shiny .
Results
MAGIC algorithm remains effective in the ATG–based haplo‐HSCT setting for predicting aGvHD, achieving AUC values of 0.693 (training), 0.658 (internal test), and 0.622 (external validation). Among candidate cytokines, a combination of ST2, REG3α, and Elafin (the HAG model) demonstrated the highest predictive accuracy. MR analysis leveraging external GWAS data supported potential causal associations of ST2 (OR = 1.280, p = 0.004), REG3α (OR = 1.300, p = 0.012), and Elafin (OR = 1.209, p = 0.039) with aGvHD risk, providing complementary biological support for their selection as candidate biomarkers. The HAG model displayed good discrimination for aGvHD (AUC = 0.636–0.701) and SR‐aGvHD (AUC = 0.666–0.779). Integration of clinical factors further enhanced prediction (HAG‐C model, wAUC from 0.682 to 0.701).
Conclusion
The HAG model, incorporating ST2, REG3α, and Elafin, provides clinically meaningful prediction of aGvHD and related clinical outcomes in ATG–based haplo‐HSCT recipients, and may serve as a mechanistically informed tool for risk stratification and clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China, s…
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China, scu.edu.tw.
- Department of Medicine I, Faculty of Medicine, University Medical Center, University of Freiburg, Freiburg, Baden-Württemberg, Germany, uni-freiburg.de.
- State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Chi…
ORCID-Profile: Yiyin Chen, Xinghao Yu, Xiaoxia Hu, Yang Xu
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- National Key Research and Development Program of China
- Science and Technology Program of Suzhou
- Suzhou Basic Research Youth Special Project
- Jiangsu Provincial Health Commission Project
- First Affiliated Hospital of Soochow University
Zitieren
APA
Chen, Y., Yu, X., Jin, Z., Jiang, C., Hu, X., & Xu, Y. (2026). Development and Validation of a Cytokine‐Based Predictive Model for Acute GvHD and Composite Outcomes in ATG–Based Haploidentical Hematopoietic Stem Cell Transplantation. Mediators of Inflammation, 2026(1). https://doi.org/10.1155/mi/3165406
Vancouver
Chen Y, Yu X, Jin Z, Jiang C, Hu X, Xu Y. Development and Validation of a Cytokine‐Based Predictive Model for Acute GvHD and Composite Outcomes in ATG–Based Haploidentical Hematopoietic Stem Cell Transplantation. Mediators of Inflammation. 2026;2026(1). doi:10.1155/mi/3165406
BibTeX
@article{Chen2026,
author = {Chen, Yiyin and Yu, Xinghao and Jin, Zhou and Jiang, Chuanhe and Hu, Xiaoxia and Xu, Yang},
title = {Development and Validation of a Cytokine‐Based Predictive Model for Acute GvHD and Composite Outcomes in ATG–Based Haploidentical Hematopoietic Stem Cell Transplantation},
journal = {Mediators of Inflammation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/mi/3165406}
}
EUVIMED